Top News in R&D
 
 

 

 

READ ONLINE

 

 
 
 
 Global Health Technologies Coalition 
 
 
 
 

 

R&D News Roundup: September 3, 2024

 

Top News in R&D

WHO invites makers of mpox tests for emergency review in push for rapid access
Reuters (8/29)

On Thursday, the World Health Organization (WHO) asked manufacturers to submit mpox diagnostic tests for emergency review in an effort to speed up and broaden access to effective testing amid the mpox emergency on the African continent. WHO has also updated its mpox testing guidance and is working with countries to roll out testing, with 30,000 tests expected to arrive in African countries in the coming weeks. Manufacturers Labcorp and Roche have also said that they are working to increase their mpox testing capacity.

CEPI partners with Afrigen to speed up mRNA vaccine development and access
CEPI press release (8/26)

The Coalition for Epidemic Preparedness Innovations (CEPI) will provide $2.05 million to South African biotech company Afrigen Biologics for a proof-of-concept project to investigate whether synthetic DNA could serve as an alternative to the traditional plasmid DNA used for mRNA vaccine development, cutting timelines and costs. The partnership supports the 100 Days Mission of reducing vaccine development timelines to just 100 days after identifying a disease outbreak with pandemic potential. The project could help further optimize mRNA vaccine development—which is already much faster and more flexible than traditional vaccines—in the face of an outbreak, as well as enable local manufacturing of vaccines in Africa, which could help facilitate more equitable access to vaccines.

First-ever Phase 2 Lassa vaccine clinical trial now fully active across West Africa
IAVI feature (8/26), features CEPI

Last week, IAVI announced that the first participants at trial sites in Ghana, Liberia, and Nigeria had been vaccinated in a clinical trial of IAVI’s Lassa fever candidate. Lassa fever, for which there is limited treatment and no available vaccine, causes an estimated 300,000 cases across West Africa annually, and the threat is expected to grow due to climate change and population growth. The trial, funded by CEPI and designed in consultation with in-country partners, will evaluate the candidate’s safety, tolerability, and immunogenicity at two different dosage levels in adults, including people living with HIV, as well as in adolescents and children two years and older. The trial results are expected in 2025.

 

 

News from GHTC

Health access groups push Gavi, UNICEF to negotiate fair price of mpox vaccines for equitable rollout
Public Citizen statement (8/27)

A Lassa vaccine is urgently needed to save thousands of lives
CEPI article (8/27), features IAVI

Eswatini to roll out first women-controlled HIV prevention product
International Planned Parenthood Federation press release (8/27), features Population Council

 

 

Highlights From the Week

 

 

AVIAN FLU R&D Roundup

 

 

Mpox R&D Roundup

 

 

Upcoming Events

September 11
Webinar: "Innovations in GPP"
Virtual

September 17-18
2024 National Health Research Forum
Virtual; Washington, DC

September 19
Webinar: "An introduction to antibiotic research and development (R&D)"
Virtual

September 26
UNGA side event on gender-responsive climate policies for health equity
New York, New York

October 8-10
Global Forum on TB Vaccines
Rio de Janeiro, Brazil

November 13-17
ASTMH Annual Meeting
New Orleans, Louisiana

November 18-21
2024 Global Health Landscape Symposium
Virtual; Washington, DC

December 5
GHIT R&D Forum 2024
Tokyo, Japan